Dr. Reddy's Laboratories has secured European Commission marketing approval for AVT03, a biosimilar to Prolia and Xgeva, used ...

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has ...

Pharma maker Dr. Reddy’s Laboratories Ltd. today announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).

Teva Pharma receives European marketing approvals for Ponlimsi, biosimilar to Prolia and Degevma, biosimilar to Xgeva: Tel Aviv, Israel Thursday, November 27, 2025, 11:00 Hrs [IST ...

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).

Hyderabad: Dr Reddy's Laboratories has announced that the European Commission has granted marketing authorization for AVT03, ...

Dr. Reddy’s secures European Commission approval for AVT03, a biosimilar of Prolia and Xgeva, enhancing its market presence.

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA e ...

Osteoporosis occurs more commonly in women, for whom medical guidelines recommend universal screening after age 65. But about ...

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...

Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis ...